Alzinova AB
Edit

Alzinova AB

http://www.alzinova.com/
Last activity: 29.03.2023
Categories: BioTechDevelopmentDrugGrowthHealthTechMarketMedtechTechnology
Alzinova AB is a Swedish clinical-stage biopharma company developing treatments for Alzheimer’s disease by specifically targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that has unique ability and precision to target the toxic amyloid-beta oligomers involved in the onset and progression of the disease. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The Company’s Certified Advisor on Nasdaq First North Growth Market is Corpura info@corpura.se +46 768-532 822.
Followers
1.22K
Mentions
44
Location: Sweden, Gothenburg
Employees: 11-50
Total raised: $357.33K
Founded date: 2011

Investors 2

Funding Rounds 2

DateSeriesAmountInvestors
10.02.2022-$304.63K-
28.02.2017Grant$52.7K-

Mentions in press and media 44

DateTitleDescriptionSource
29.03.2023Startup Showcase: Alzinova AB – Pioneering Alzheimer’s Disea...Alzinova AB is a Swedish biotechnology company engaged in drug discovery research for Alzheimer’s di...eustartup....
01.11.2022Alzinova AB interim report January – September 2022Alzinova AB interim report January – September 2022 Tue, Nov 01, 2022 08:01 CET Report this content ...news.cisio...
07.09.2022Alzinova announces new positive safety review of its Phase 1...Alzinova announces new positive safety review of its Phase 1b study in Alzheimer’s disease Wed, Sep ...news.cisio...
25.08.2022Alzinova AB interim report January – June 2022Alzinova AB interim report January – June 2022 Thu, Aug 25, 2022 08:01 CET Report this content The B...news.cisio...
03.08.2022Alzinova has recruited half of the patients for the ongoing ...Alzinova has recruited half of the patients for the ongoing Phase 1b study of the vaccine candidate ...news.cisio...
05.07.2022Alzinova establishes scaled-up manufacturing process for ALZ...Alzinova establishes scaled-up manufacturing process for ALZ-101 ahead of Phase 2 Tue, Jul 05, 2022 ...news.cisio...
01.07.2022Conversion of BTU into shares and warrants of series TO3Conversion of BTU into shares and warrants of series TO3 Fri, Jul 01, 2022 12:33 CET Report this con...news.cisio...
15.06.2022Alzinova announces outcome of rights issueAlzinova announces outcome of rights issue Wed, Jun 15, 2022 08:01 CET Report this content Alzinova ...news.cisio...
08.06.2022Alzinova appoints Mangold Fondkommission as new liquidity pr...Alzinova appoints Mangold Fondkommission as new liquidity provider Wed, Jun 08, 2022 08:01 CET Repor...news.cisio...
30.05.2022The subscription period in Alzinova’s rights issue starts to...The subscription period in Alzinova’s rights issue starts today Mon, May 30, 2022 08:01 CET Report t...news.cisio...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In